Pseudoxanthoma Elasticum Clinical Trial
Official title:
Efficacy of PyROphosPHate Supplementation to Fight ECtopIc Calcification in PseudoXanthoma Elasticum - PROPHECI-PPI Study
Pseudoxanthoma elasticum (PXE) is a rare inherited metabolic disorder (OMIM 264800, frequency 1/25000) characterized by progressive ectopic calcification of connective tissues. PXE mainly affects the skin (inesthetic papules and plaques in the skin folds), the retina (central blindness), the vasculature (peripheral arterial occlusive disease and stroke) and the renal system (renal lithiasis) in adulthood. Although rarely, early lethal forms have been reported. This chronic and highly disabling condition results from a loss of function of the gene encoding for the ABCC6 membrane transporter primarily expressed in the hepatocytes and renal tubular cells. Recently, it has been reported that PXE was characterized by a 50-60% decrease in the plasma level of inorganic pyrophosphate (PPi), a major physiological anti-calcifying factor. PXE is an incurable disease which therapeutic options are limited to symptomatic treatments to stem the devastating effect of the ectopic calcifications. Recently, encouraging proof of concept studies with animals PXE models and healthy volunteers have shown that, contrary to what was initially reported and thought, the oral administration of PPi salts are able to increase PPi plasma levels, opening up new therapeutic perspectives in PXE. Therefore, we propose to perform the first Phase II randomized controlled trial (RCT) to evaluate the safety and efficacy of a daily and oral administration of PPi salts against placebo in PXE patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02537054 -
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
| Active, not recruiting |
NCT05569252 -
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
|
Phase 2 | |
| Recruiting |
NCT05662085 -
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
|
||
| Completed |
NCT03070860 -
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
|
N/A | |
| Completed |
NCT01446393 -
Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)
|
N/A | |
| Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03758534 -
Natural History of GACI With or Without ARHR2 or PXE
|
||
| Recruiting |
NCT01446380 -
Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
|
N/A | |
| Recruiting |
NCT03813550 -
Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
|
N/A | |
| Not yet recruiting |
NCT03364504 -
Biological Collection of Kidney Cells
|
N/A | |
| Active, not recruiting |
NCT02108392 -
Characterization of Pseudoxanthoma Elasticum
|
||
| Recruiting |
NCT01731080 -
Arterial Wall Calcium Load in Pseudoxanthoma Elasticum
|
N/A | |
| Completed |
NCT00555113 -
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
|
N/A | |
| Completed |
NCT00341419 -
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
|
||
| Withdrawn |
NCT04441671 -
Oral Pyrophosphate Absorption in PXE Disease
|
Phase 2 | |
| Completed |
NCT05025722 -
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
|
||
| Completed |
NCT01525875 -
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
| Completed |
NCT05246189 -
Employment of Patients With Pseudoxanthoma Elasticum
|
||
| Recruiting |
NCT05832580 -
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum
|
Phase 3 | |
| Active, not recruiting |
NCT05030831 -
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
|
Phase 1/Phase 2 |